FDA Issues Not Substantially Equivalent Order on Maverick Menthol Product

Retailers have 30 days to remove Maverick Menthol Silver Box 100s cigarettes from inventory

WASHINGTON -- On July 14, the U.S. Food and Drug Administration (FDA) issued a Not Substantially Equivalent (NSE) order on ITG Brand’s Maverick Menthol Silver Box 100s cigarettes, NATO reported. The FDA determined that these menthol cigarettes were not substantially equivalent to another cigarette product on the market as of the Feb. 15, 2007, “grandfather” date. The decision means Maverick Menthol Silver Box 100s cigarettes cannot be sold or distributed as of the issuance of the FDA’s NSE order on July 14.

Maverik Menthol cigarettes

However, as with previous NSE orders, the FDA stated it will not enforce action against retailers with Maverick Menthol Silver Box 100s currently in inventory for at least 30 calendar days from the July 14 order date.

“This policy applies only to Maverick Menthol Silver Box 100s already in a retail store that offers products for sale to customers,” NATO reported in a news bulletin. “This means that retailers are allowed to sell through their inventory of Maverick Menthol Silver Box 100s until Aug. 13, 2016, at which time the sale of Maverick Menthol Silver Box 100s must be stopped.”

This FDA NSE order does not apply to other styles of Maverick cigarettes, which can continue to be distributed and sold.

Click here to read Brief Summary of “Not Substantially Equivalent” Determinations

Members help make our journalism possible. Become a CSP member today and unlock exclusive benefits, including unlimited access to all of our content. Sign up here.


Exclusive Content

Snacks & Candy

Convenience-Store Shoppers Are Sweet on Private-Label Candy

How 7-Eleven, Love’s are jumping on confection trends


How to Make the C-Store the Hero for Retail Media Success

Here’s what motivates consumers when it comes to in-store and digital advertising

Mergers & Acquisitions

Soft Landing Now, But If Anyone Is Happy, Please Stand Up to Be Seen

Addressing the economic elephants in the room and their impact on M&A


More from our partners